Flamingo Therapeutics Is A Clinical Stage Biotechnology Company Dedicated To Developing Rna Targeted Therapies For Oncologyformed In 2023 Through A Merger With Dynacurethe Company Combines Expertise In Rna Therapeutics And Oncology Drug Developmentled By Ceo Sta Phane Van Rooijenflamingo Focuses On Overcoming Challenges In Treating Resistant Cancers Using Advanced Antisense Oligonucleotideasotechnology The Company Specializes In Rna Therapeutic Drug Developmentutilizing Proprietary Backbone Chemistries To Enhance The Stability And Efficacy Of Asosflamingo S Pipeline Includes Danvatirsena Stat3 Inhibiting Aso Currently In Phase 2 Trials For Recurrent Metastatic Head And Neck Squamous Cell Carcinoma And Relapsed Refractory Aml Mdsadditionallyflm 7523A Malat1 Targeting Asois In Preclinical Development Aimed At Inhibiting Cancer Metastasis And Progressionflamingo Prioritizesundruggableoncology Targets And Collaborates With Clinical Trial Partners And Pharmaceutical Collaborators To Advance Its Innovative Therapies
